We amplified, cloned, and sequenced the ␤-tubulin gene of Vittaforma corneae, a microsporidium causing human infections. The ␤-tubulin gene sequence has a substitution at Glu 198 (with glutamine), which is one of six amino acids reported to be associated with benzimidazole sensitivity. Benzimidazoles were assayed for antimicrosporidial activity and showed poor parasite inhibition.
amplified, cloned, and sequenced the ␤-tubulin gene of V. corneae.
MRC-5 cells were seeded on 24-well culture plates at a concentration of 5 ϫ 10 5 /ml in minimal essential medium and incubated overnight to confluence. Confluent monolayers of cells were inoculated with 2 ϫ 10 6 microsporidian spores (V. corneae and E. cuniculi as a control). Three hours later, noninternalized spores were washed off and fresh medium with or without drugs was added. Albendazole and fenbendazole were purchased from Sigma (St. Louis, MO), and stock solutions were dissolved in dimethyl sulfoxide at a final concentration of 10 mg/ml and thereafter diluted in culture medium for use in the assay. Culture medium was replaced every 3 days, and on day 10, 100 l of 10% (wt/vol) sodium dodecyl sulfate was added to each well to release newly developed spores from infected host cells. The spores were counted in a hemocytometer. Each treatment was done in triplicate, and the percent inhibition of microsporidian replication was calculated as 100 Ϫ [(number of spores counted in treated culture/number of spores in nontreated cultures) ϫ 100]. Comparison of antimicrosporidial activities was done by Student's t test.
DNA was isolated from V. corneae-infected cell cultures, and the ␤-tubulin sequences were amplified with the degenerate primers btubf (5Ј-GCC TGC AGG NCA RTG YGG NAA YCA-3Ј) and btubr (5Ј-GGC CTC AGT RAA YTC CAT YTC RTC CAT-3Ј) (15) . PCR fragments were ligated into the vector pCR4-TOPO (Invitrogen, Carlsbad, CA) and cloned into TOP10 competent cells (Invitrogen). Plasmids were isolated from white colonies and sequenced on an automated DNA sequencer (ABI PRISM, Applied Biosystems, Foster City, CA) with vector-directed primers T7 and M13. Sequencing of both strands of each PCR fragment was done twice, and several plasmids were sequenced. The resulting DNA sequences were assembled with GeneTool Lite, version 1.0, and a consensus sequence was generated.
Results in Fig. 1 demonstrated that albendazole displayed significantly lower (P Ͻ 0.001) antimicrosporidial in vitro activities against V. corneae compared to E. cuniculi. Significant antimicrosporidial activities were observed in E. cuniculi cultures treated with albendazole or fenbendazole at concentrations of 10 ng/ml and above, whereas in V. corneae cultures no antimicrosporidial activities could be detected up to 1,000 ng/ ml. At concentrations of 1,000 ng/ml, clear signs of host cell toxicity were observed after treatment of host cells with albendazole or fenbendazole for 10 days.
PCR amplification revealed a DNA fragment that was ϳ1,000 bp long. Sequencing of the cloned DNA fragment provided a 1,024-bp gene sequence with a CG content of 46%. The predicted ␤-tubulin amino acid sequence has only five of the six sites that have been reported to be associated with benzimidazole activity (His 6 is not included, as the fragment is truncated at the 5Ј end) and has a substitution at Glu 198 (with glutamine) (numbering is based on the Saccharomyces cerevisiae sequence in Fig. 2 ).
Some microsporidia (especially the Encephalitozoon spp.) and other protists (e.g., Giardia lamblia and Cryptococcus neoformans) are very sensitive to several derivatives of a group of drugs called the benzimidazoles, which are widely used to treat helminth infections in humans and animals and as systemic fungicides in agriculture (13, 17) . Benzimidazoles have been shown to disrupt mitosis in sensitive organisms through binding to the ␤-tubulin subunit of microtubules. The benzimidazole binding site and the basis for the selective toxicity of these compounds remain incompletely defined (17) . Six amino acids of ␤-tubulin are reported to be associated with benzimidazole sensitivity (His 6 , Ala 165 , Phe 167 , Glu 198 , Phe 200 , and Arg 241 ; numbering is based on the S. cerevisiae sequence in Fig. 2) (7, 8, 13, 14, 16, 24) . The ␤-tubulin amino acid fragment of V. corneae has a substitution at Glu 198 (with glutamine), which suggests resistance to benzimidazoles. The same substitution was found recently in the ␤-tubulin gene of E. bieneusi, another human-infecting microsporidium with clinically observed resistance to benzimidazoles (1). Several papers have indicated that V. corneae and E. bieneusi evolved simultaneously and are closely related microsporidia. The ␤-tubulin data presented here support this relationship, and V. corneae may be a useful surrogate organism for studies on Enterocytozoon drug resistance; such studies have so far been hampered as E. bieneusi could not be cultivated in long-term culture.
Organisms resistant to benzimidazoles lack one or more of the six amino acids mentioned above. Besides E. bieneusi, Entamoeba histolytica also has changes at Glu 198 and is relatively resistant to albendazole, and Cryptosporidium parvum and Acanthamoeba polyphaga, which have an additional change at Phe 200 (in addition to Glu 198 ), are resistant to benzimidazoles as well. V. corneae has Ala 165 , whereas E. cumiculi, E. hellem, and E. intestinalis have a change from Ala 165 to Cys 165 . Nevertheless, V. corneae is resistant to benzimidazoles, whereas the Encephalitozoon spp. are highly susceptible. Cys 165 is also present in G. lamblia and C. neoformans, which are sensitive to albendazole (7, 16, 17) . So changes in Glu 198 and/or Phe 200 seem to be associated with resistance to benzimidazoles, whereas changes in Ala 165 seem not to be highly predictive of benzimidazole sensitivity.
The suspected resistance against albendazole was further evaluated in vitro. Previous studies have shown inconsistent results. In one study, albendazole at 2.1 or 4.2 g/ml in minimal essential medium was tested against V. corneae in MDCK cell monolayers and showed some antimicrosporidial activity (22) . The percentage of infected cells was reduced in the presence of the drug, and there were ultrastructural abnormalities at all stages of the life cycle. The drug prevented parasite division (22) . However, such high concentrations cannot be reached under therapy. In another study, albendazole was less effective against V. corneae than against E. intestinalis, based on an approximately sevenfold higher minimal inhibitory concentration for 50% of the isolates tested (4). The in vitro data presented here also show that benzimidazoles are not effective against V. corneae whereas E. cuniculi parasite growth was inhibited very effectively. There are limited clinical data about the application of albendazole in Vittaforma infections. One patient with keratitis due to V. corneae was treated with topical steroids and broad-spectrum antibiotics but ultimately required a corneal transplant (2). Another patient was treated initially with topical acyclovir and steroid, but penetrating keratoplasty was performed later and he was given two courses of oral albendazole (400 mg daily), each for 14 days, and no microsporidia were detected in a biopsy of the rejected graft 6 months later (18) . A third patient underwent penetrating keratoplasty as well but was not treated with albendazole (10), and another patient was treated with both topical fumagillin bicyclohexylammonium salt and oral albendazole but failed to improve or control the progression of the infection after lamellar keratoplasty (9) . Thus, there is no clinical evidence for or against the use of albendazole in Vittaforma infections. Our experimental data show resistance of V. corneae to benzimidazoles. The molecular data obtained suggest that V. corneae should be resistant to benzimidazoles, and this was shown in vitro. Infections with V. corneae should not be treated with benzimidazoles, and other treatment options, such as fumagillin or TNP-470, should be chosen. Nucleotide sequence accession number. The consensus sequence generated from several sequencing reactions in this study was submitted to the GenBank database under accession no. EU031749. 
